At a median follow-up of 53 months, the median PFS was not reached with KRd and was 48.8 months with VRd. Carfilzomib, lenalidomide, and dexamethasone (KRd) significantly prolonged progression-free ...
KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...
Patients with newly diagnosed multiple myeloma often receive twice-weekly triplet regimens of carfilzomib, lenalidomide, and dexamethasone (KRd). New data suggest less frequent dosing can be equally ...
Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211). This is an ASCO Meeting ...
“Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®. Patients with newly diagnosed multiple myeloma treated with the four-drug combination of Sarclisa (isatuximab) ...
RIO DE JANEIRO — A quadruplet induction regimen of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in the treatment of newly diagnosed multiple myeloma (MM) shows a notably high ...
The acquisition of two Chicago-based firms creates a new market for Aprio, reinforces commitment to expanding its position across the U.S. "We are pleased to expand our footprint into the greater ...
In 2011, a group of experts in different fields like solar photovoltaics, renewable energies, business internationalization, and foreign investments, led by the co-founders: Sergio Cardamas and Oscar ...
KRD Vision, a Delhi based boutique consulting company, assists business leaders across the globe in making informed confident business strategy decisions that are backed by judgement, logic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results